儿童分化型甲状腺癌侵袭性组织学与独特分子特征相关
回顾性分析2001至2017年匹兹堡大学医学中心71例小于19岁分化型甲状腺癌患者的分子检测结果,92%存在基因改变,BRAF样基因融合与更高肿瘤分期、多灶性疾病和淋巴结转移相关,术前分子检测可能有助于指导初始手术范围。
要点
- 儿童分化型甲状腺癌患者中92%可检出基因改变,BRAF样改变占55%。
- BRAF样基因融合与更高肿瘤分期、多灶病变和淋巴结转移相关。
- ETV6/NTRK3融合与更高肿瘤分期相关,BRAF样点突变与因复发再次手术风险相关。
核心结论
- 在行全面分子检测的儿童甲状腺癌队列中,超过90%存在可识别的基因改变,侵袭性特征主要与BRAF样基因融合相关。
- 术前分子检测结果可能有助于指导小于19岁甲状腺癌患者初始手术的范围。
研究设计与样本
- 回顾性综述纳入2001至2017年匹兹堡大学医学中心诊断的年龄小于19岁的分化型甲状腺癌患者,共71例有分子检测结果。
- 组织学重新复核以确认诊断并确定用于下一代测序(ThyroSeq第3版,TSv3)的组织,采用回归分析评估与组织学和临床特征的相关性。
主要发现
- 71例有分子检测结果的患者中62例(87%)为甲状腺乳头状癌,中位随访6年(范围18天至18年)时所有患者均存活。
- 65例(92%)患者检出基因改变,其中BRAF样点突变或融合39例(55%),RAS样突变或融合21例(30%),拷贝数改变5例(7%)。
- 在甲状腺乳头状癌患者中校正性别和肿瘤大小后,多因素回归分析显示更高肿瘤分期(β:0.234,p < 0.001)、多灶性疾病(比值比[OR]:3.60,p = 0.042)和淋巴结转移(OR:6.13,p = 0.044)与BRAF样基因融合相关。
- ETV6/NTRK3融合与更高肿瘤分期相关(β:2.07,p = 0.023),BRAF样点突变与随时间因复发接受手术的可能性增加相关(风险比:19.5,p = 0.004)。
临床怎么用
- 作者认为术前分子检测结果可能有助于指导小于19岁甲状腺癌患者初始手术的范围。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Molecular testing (MT) enhances the diagnostic accuracy of thyroid fine-needle aspiration biopsy, reducing the need for diagnostic lobectomy in adult patients with indeterminate nodules (Bethesda class III/IV). However, little is known about genetic alterations in pediatric thyroid carcinoma (TC). Our aim was to analyze MT results of pediatric differentiated TC (DTC) cases to determine associations with histological and clinical features. Methods: A retrospective review identified all patients (aged <19 years) diagnosed with DTC from 2001 to 2017 at the University of Pittsburgh Medical Center. Histology was rereviewed to confirm diagnosis and identify tissue for MT using next-generation sequencing (ThyroSeq, version 3, TSv3). Correlation with histological and clinical features was analyzed using regression analysis. Results: Of 71 patients with MT results, 62 (87%) patients had papillary TC. All patients were alive at a median follow-up of 6 years (range 18 days to 18 years). Genetic alterations were identified in 65 (92%) patients. These alterations were grouped as BRAF-like point mutations or fusions (39, 55%), RAS-like mutations or fusions (21, 30%), or copy number alterations (5, 7%). On multiple regression analysis accounting for patient sex and tumor size in patients with papillary TC, increased tumor stage (β: 0.234, p < 0.001), multifocal disease (odds ratio [OR]: 3.60, p = 0.042), and lymph node metastases (OR: 6.13, p = 0.044) were associated with BRAF-like gene fusions. When considering individual mutations, ETV6/NTRK3 fusions were associated with increased tumor stage (β: 2.07, p = 0.023) and BRAF-like point mutations were associated with increased likelihood of surgery for recurrence over time (hazard ratio: 19.5, p = 0.004). Conclusions: Among our cohort of pediatric TC patients who underwent comprehensive MT, >90% had an identifiable genetic alteration. Aggressive features were primarily associated with BRAF-like gene fusions. Preoperative MT results may be useful in guiding the extent of the initial operation in pediatric patients (aged <19 years) with TC.
引用
- Mollen KP, Shaffer AD, Yip L, et al. Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer. Thyroid. 2022. PMID: 34915753. doi:10.1089/thy.2021.0317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。